Riverpark Capital Management adds Illumina (ILMN) to its portfolio

Illumina (ILMN) : Riverpark Capital Management added new position in Illumina during the most recent quarter end. The investment management firm now holds 14,843 shares of Illumina which is valued at $2,449,837 , the company said in a statement filed on Aug 1, 2016 with the SEC.Illumina makes up approximately 1.11% of Riverpark Capital Management’s portfolio.

Other Hedge Funds, Including , Whittier Trust Co boosted its stake in ILMN in the latest quarter, The investment management firm added 1,188 additional shares and now holds a total of 17,775 shares of Illumina which is valued at $2,956,871. Illumina makes up approx 0.13% of Whittier Trust Co’s portfolio.Capstone Asset Management Co boosted its stake in ILMN in the latest quarter, The investment management firm added 1,257 additional shares and now holds a total of 14,307 shares of Illumina which is valued at $2,086,819. Illumina makes up approx 0.06% of Capstone Asset Management Co’s portfolio.Cutler Group Lp reduced its stake in ILMN by selling 1,019 shares or 4.24% in the most recent quarter. The Hedge Fund company now holds 22,987 shares of ILMN which is valued at $3,352,884. Illumina makes up approx 0.23% of Cutler Group Lp’s portfolio.Dnb Asset Management As boosted its stake in ILMN in the latest quarter, The investment management firm added 300 additional shares and now holds a total of 11,489 shares of Illumina which is valued at $1,622,821. Illumina makes up approx 0.03% of Dnb Asset Management As’s portfolio.

Illumina opened for trading at $164.63 and hit $167 on the upside on Thursday, eventually ending the session at $165.66, with a gain of 0.37% or 0.61 points. The heightened volatility saw the trading volume jump to 5,53,667 shares. Company has a market cap of $24,385 M.

On the company’s financial health, Illumina reported $0.71 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.74. The company had revenue of $571.80 million for the quarter, compared to analysts expectations of $580.44 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.

Many Wall Street Analysts have commented on Illumina. Company shares were Reiterated by Mizuho on Jul 27, 2016 to “Neutral”, Firm has raised the Price Target to $ 148 from a previous price target of $138 .Shares were Downgraded by Morgan Stanley on Jul 5, 2016 to ” Underweight” and Lowered the Price Target to $ 110 from a previous price target of $130 .Illumina was Initiated by CL King to “Buy” on Jun 22, 2016.

Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Illumina - Is it time to Sell?

Top Brokerage Firms are advising their investors on Illumina. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.